Introduction
============

Terminal differentiation of a cell is marked by its functional specialization and irreversible loss of proliferation ability. Skeletal muscle cells, such as C2C12, are a well characterized model system to study this process. In vitro, myoblasts deprived of growth factors enter an irreversible postmitotic state and activate the expression of muscle-specific genes, thus becoming myocytes. Myocytes, in turn, can fuse into multinucleated, syncytial structures called myotubes ([@bib25]). Terminally differentiated (TD)[\*](#fn1){ref-type="fn"} myotubes can be induced to enter the cell cycle by growth factors. However, they cannot progress beyond a mid-G~1~ block, and hence do not enter the S phase ([@bib31]). Even forced expression of cell cycle regulators, such as E2Fs or the cyclin E (cycE)--cyclin-dependent kinase 2 (cdk2) complex, is unable to trigger DNA synthesis in TD muscle cells ([@bib28]; [@bib26]; [@bib18]). Conversely, early gene products of DNA tumor viruses, such as adenovirus E1A, are able to stimulate S phase entry of quiescent or TD cells ([@bib5]; [@bib32]). Thus, they constitute a powerful tool to study how postmitotic cells can be forced to proliferate, an issue of great relevance to the understanding of human cancer.

The E1A region of human adenovirus 5 produces two major mRNAs, 12S and 13S, which encode nuclear proteins of 243 and 289 amino acids, respectively. The 12S variant of E1A (hereafter referred to as E1A) is sufficient to promote cell cycle reentry and S phase in TD myotubes ([@bib32]) by a mechanism that is only partially elucidated. E1A displays multiple interactions with key components of cellular growth-regulatory pathways, including retinoblastoma protein (pRb)-family proteins (the so-called pocket proteins) and the transcriptional coactivators p300 and CBP ([@bib3], [@bib4]). Although these interactions are required for the ability of E1A to immortalize and transform cells ([@bib9]), its capacity to reactivate the cell cycle segregates with binding to pocket proteins, whereas binding to p300 is not required ([@bib30]; [@bib32]; [@bib27]).

Binding of E1A to pocket proteins releases transcription factors of the E2F family ([@bib24]) that are master regulators of the G~1~/S transition and are able to induce DNA synthesis in a variety of quiescent, non-TD cells ([@bib16]; [@bib19]). E2Fs act in part by transcriptionally up-regulating the kinase activity of the cycE--cdk2 complex ([@bib22]). However, neither the overexpression of several E2Fs nor that of cycE--cdk2 could force the reentry into S phase of TD myotubes ([@bib26]; [@bib18]). Thus, E1A must be activating complementary pathways that contribute to the G~1~/S transition of TD myotubes. An investigation of such pathways is warranted by both their central role in the control of cell proliferation and their possible alterations in neoplastic cells. The present studies were undertaken in an attempt to elucidate this issue.

Results and discussion
======================

Np95 is induced early in the reentry of TD myotubes in the cell cycle
---------------------------------------------------------------------

To gain insight into the molecular mechanisms leading to reactivation of TD cells, we used a cDNA subtraction approach to identify genes induced by E1A in TD myotubes. TD C2C12 mouse myotubes were infected with either the adenovirus *dl520*, which expresses only the 12S E1A mRNA, or the control adenovirus *dl312*, in which the E1A gene is deleted ([@bib17]). The efficiency of S phase reentry, measured 48 h after *dl520* infection, was ∼70--80% ([Fig. 1](#fig1){ref-type="fig"} A). To select for genes induced by E1A at early stages, mRNAs from infected cells were harvested at 14, 15, 16, 18, 20, and 24 h after infection. These time points precede (by at least 6 h) the onset of DNA replication (occurring ∼30 h after infection). Pooled mRNAs were used for the cDNA subtraction procedures (see Materials and methods).

![**Np95 is an early E1A-induced gene.** (A) TD myotubes were infected with either *dl520* (left, MOI, 400 pfu/cell) or *dl312* as a control (right, MOI, 400 pfu/cell). 24 h later, cells were treated with BrdU. 48 h after infection, cells were fixed and stained with anti--myosin heavy chain (red) to check differentiation and anti-BrdU (green) antibodies. Nuclear counterstaining was performed with DAPI (blue). (B) Schematic of mouse Np95; the various domains of the protein are indicated (Ubl, ubiquitin-like; NLS, nuclear localization signal). Two putative pRb-binding motifs, LxCxE and IxCxE ([@bib6]), are indicated by asterisks. (C) TD myotubes were infected with either *dl520* (MOI, 400 pfu/cell) or *dl312* (MOI, 400 pfu/cell), and mRNA or proteins were harvested at the indicated time points. RNAs (2 μg Poly(A)^+^, top) were analyzed in Northern blot (NB) with the indicated probes. Proteins (40 μg of total cellular lysates, bottom) were immunoblotted (IB) with the indicated antibodies. pRb and ph-pRb are a pan--anti-pRb and a specific anti-phosphoRb, respectively (see Materials and methods). The levels of Np95 before (myoblasts) and after (myotubes) differentiation are also shown.](0201025f1){#fig1}

Among the genes induced by E1A, we isolated Np95, which encodes a previously described murine nuclear phosphoprotein, and whose expression is cell cycle regulated ([@bib11]; [@bib33]; [@bib21]; [Fig. 1](#fig1){ref-type="fig"} B). [Fig. 1](#fig1){ref-type="fig"} C shows the mRNA and protein expression of Np95, before and after terminal differentiation of C2C12 cells, and after their reentry in the cell cycle induced by infection with *dl520*. The expression of Np95 was virtually abolished by terminal differentiation, both at the mRNA and protein levels ([Fig. 1](#fig1){ref-type="fig"} C, compare Myoblasts with Myotubes), and reinduced by infection with *dl520*, but not with *dl312*. Np95 mRNA and protein started to be detectable ∼15--16 h after infection, and continued to increase until the last time points were checked (20--24 h after infection; [Fig. 1](#fig1){ref-type="fig"} C). Because the expression of the E1A mRNA was first detectable at 15 h after infection (unpublished data), as also previously reported ([@bib31]), we concluded that Np95 is an early E1A-induced gene.

Np95 is specifically induced by E1A and complements cycE--cdk2 in the induction of reentry in the cell cycle of TD myotubes
---------------------------------------------------------------------------------------------------------------------------

To establish a role for Np95 in the sequence of events activated by E1A, we performed a series of experiments. First, we investigated the induction of Np95 by different stimuli. As shown in [Fig. 2](#fig2){ref-type="fig"} A, overexpression of E1A (*dl520* lane) potently induced the expression of Np95. Stimulation with serum, or overexpression of either E2F-1 or of cycE--cdk2, only exerted minute effects ([Fig. 2](#fig2){ref-type="fig"} A), possibly attributable to a small percentage of myoblasts contaminating the myotube cultures. As a control, we checked the levels of cycE and the phosphorylation status of pRb. As expected, both E1A and E2F-1 induced the expression of cycE ([@bib32]; [@bib26]), whereas both E1A and cycE--cdk2, but not E2F-1, induced hyperphosphorylation of pRb ([@bib32]; [@bib26]; [@bib20]; [@bib18]; [Fig. 2](#fig2){ref-type="fig"} A). Thus, in TD myotubes Np95 expression depends essentially on the activation by E1A of pathways besides those relying on the stimulation of the activity of the cycE--cdk2 complex or the presence of high levels of free E2F-1.

![**Role of Np95 in the reentry in the cell cycle of TD myotubes.** (A) TD myotubes were infected with *dl520* (MOI, 400 pfu/cell), *dl312* (MOI, 400 pfu/cell), or adenoviral vectors encoding E2F-1 (MOI, 400 pfu/cell), cycE (MOI, 100 pfu/cell)/cdk2 (MOI, 400 pfu/cell), or stimulated with 5% FCS, as indicated on top. 48 h after infection, total cellular lysates were extracted and immunoblotted (40 μg) with the indicated antibodies. Lanes myoblasts and myotubes are as in [Fig. 1](#fig1){ref-type="fig"} C. (B) TD myotubes were infected with adenoviral vectors, as indicated on the right. MOIs were as follows: cycE, 100 pfu/cell; cdk2, 400 pfu/cell; and Np95, 60 pfu/cell. 24 h later, cells were treated with BrdU. 48 h after infection, cells were fixed and stained with anti-BrdU (red), and either anti--myosin heavy chain (green, top two rows, MHC), or anti-cycE (green, middle row) antibodies, or detected by epifluorescence (green, bottom two rows, to detect GFP-Np95). Nuclear counterstaining was performed with DAPI (blue). For each condition (horizontally paired panels), two pictures of the same microscopic field are shown. All left panels display the blue (DAPI) and green (either MHC, or cycE, or GFP) channels. All right panels display the green (either MHC, or cycE, or GFP) and red (BrdU) channels. Stainings are also indicated by a color code (squares).](0201025f2){#fig2}

E1A reactivates proliferation of TD muscle cells by a mechanism that includes release of E2Fs and activation of the cycE--cdk2 complex, but also requires other pathway(s) that are presently not molecularly defined ([@bib32]; [@bib18]). From these results, Np95 appears to possess the requisites to be part of such a pathway. If so, its overexpression might complement that of cycE--cdk2 toward induction of the S phase in TD myotubes. Thus, we coexpressed Np95, cycE and cdk2 in C2C12 myotubes, through adenoviral vectors. When the three proteins were coexpressed, ∼20% of the myotubes entered S phase within 60 h after infection ([Fig. 2](#fig2){ref-type="fig"} B and [Table I](#tbl1){ref-type="table"}). Conversely, no reentry in the cell cycle was induced by expression of Np95 alone, by the cycE--cdk2 combination, or several other negative controls ([Fig. 2](#fig2){ref-type="fig"} B and [Table I](#tbl1){ref-type="table"}).

###### Np95 cooperates with cycE--cdk2 to induce S phase entry of TD myotubes

  Infection[a](#tfn1){ref-type="table-fn"}   BrdU positive cells[b](#tfn2){ref-type="table-fn"}
  ------------------------------------------ ----------------------------------------------------
                                             \%

Adenoviral vectors encoding cycE, cdk2, and Np95 were used at an MOI of 100, 400, and 60, respectively. Optimal MOIs were established in preliminary experiments (unpublished data). TRACK is a control empty adenovirus used at an MOI of 120. 24 h after infection, cells were treated with BrdU and fixed 24 h later. TD myotubes were identified by staining with anti--myosin heavy chain.

350 myotubes per plate were counted and scored for BrdU positivity. The experiment shown is typical and representative of three experiments.

Np95 is essential for entry into S phase
----------------------------------------

Taken together, the previous results suggest that Np95 could be a critical effector in the progression of a cell through the cycle. The fact that Np95 cooperates with cycE--cdk2 to overcome the G~1~ block in TD cells further suggests that its action might be exerted physiologically at the G~1~/S transition. To address this question, we switched to NIH-3T3 cells in which functional ablation of the expression of a protein could be more easily achieved. In these cells, the expression of Np95 is known to be cell cycle regulated ([@bib33]; [@bib21]). Indeed, in serum-starved NIH-3T3 cells, Np95 was undetectable ([Fig. 3](#fig3){ref-type="fig"} A). Its expression started to be clearly detectable after 9 h of restimulation with serum, i.e., 6 h before the onset of S phase ([Fig. 3](#fig3){ref-type="fig"} B). These results mirrored those obtained in TD myotubes stimulated with E1A, and suggested the reactivation of Np95 occurs by similar mechanisms in cells that display either a reversible or an irreversible cell cycle arrest.

![**Cell cycle--dependent regulation of Np95 in NIH-3T3 cells.** (A) NIH-3T3 cells were serum-starved for 48 h, and then stimulated with 10% FCS for the indicated time points. (A) Immunoblots (40 μg of total proteins) with the indicated antibodies. The levels of Np95 in serum-starved cells (Starv) or in an asynchronously growing population (Async) are also shown. (B) FACS^®^ profiles: open circles, G0/G1; closed circles, S; squares, G2/M.](0201025f3){#fig3}

Next, we attempted functional ablation of Np95, by an antisense approach. Serum-starved NIH-3T3 cells were microinjected with a morpholino-modified antisense oligonucleotide of 25 bp that matched the sequence of Np95 and overlapped its ATG. As a control, we microinjected a similar oligonucleotide bearing four mismatched bases, including one in the start codon (see Materials and methods). Serum and BrdU were then added to the cells that were fixed 24 h later. As shown in [Fig. 4](#fig4){ref-type="fig"} A, the expression of Np95 and BrdU incorporation was dramatically reduced in cells microinjected with the antisense oligonucleotide, but not with the mismatched control. Around 80% of the cells microinjected with the antisense oligonucleotide were inhibited in their progression into S phase ([Fig. 4](#fig4){ref-type="fig"} B), thus demonstrating that Np95 is essential for the progression through the cell cycle.

![**Functional ablation of Np95 in NIH-3T3 cells.** (A) NIH-3T3 were serum starved for 48 h, and then microinjected with the Np95 antisense (AS) oligonucleotide or its mismatched (MIS) control. IgGs were also microinjected to identify microinjected cells. BrdU and 10% FCS were then added, and cells were fixed 24 h later and stained as indicated. Nuclear counterstaining was performed with DAPI. (B) A quantitative assessment was performed on three independent experiments, in which at least 150 microinjected cells per experiment were counted. Results are shown as a percentage of microinjected cells (±SD) that were Np95-positive (solid bars) or BrdU-positive (empty bars).](0201025f4){#fig4}

Np95: an oncogene candidate?
----------------------------

Terminal differentiation exerts a remarkably tight control on cell proliferation. Because TD cells constitute the majority in an adult mammal, the understanding of how they can be forced to reenter the cell cycle might be very relevant to human cancer. TD myotubes are extremely refractory to the mitogenic action of several oncogenes and growth-promoting inducers ([@bib32]; [@bib18]), but sensitive to the action of E1A, and therefore represents an invaluable tool to dissect critical mechanisms in cell cycle progression. Previous evidence suggests that E1A, in addition to its well characterized effects on the pRb/E2F-1 pathway, activates a parallel and complementary pathway that is also required for the reentry in S phase ([@bib32]; [@bib1], [@bib2]; [@bib18]). In this study, we show that Np95 has all the characteristics to be the first molecular determinant identified in this pathway. Np95 appears to constitute a critical effector of this pathway, because it can complement the overexpression of cycE--cdk2 toward stimulation of S phase in TD myotubes. In addition, the function of Np95 is physiologically required for progression through the cell cycle, as witnessed by its tight regulation and by the dramatic effects of its functional ablation in NIH-3T3 cells.

Many important questions remain to be addressed. How is the transcription of Np95 regulated under physiological conditions? What is the physiological function of Np95? How does it signal downstream? With regard to the first question, we note that overexpression of cycD--cdk4 was recently shown to induce S phase entry of TD myotubes ([@bib18]). Thus, it is possible that Np95 is a transcriptional target of a pathway that includes the kinase activity of this complex, a possibility that we are currently testing.

As far as the function of Np95 is concerned, a human gene (*ICBP90*) that displays remarkable similarity to mouse Np95 (74% identity and 84% overall similarity at the amino acid level), was recently isolated in a one-hybrid system as an inverted CCAAT box--interacting protein of the topoisomerase IIα promoter ([@bib15]), and shown to be involved in the transcriptional control of this gene. Although it remains to be established whether *ICBP90* and Np95 are orthologues, our results suggest the possibility that Np95 acts in transcriptional control. In addition, the presence in Np95 of many structural and functional domains, including a ubiquitin-like domain, a PHD finger, pRb-binding motifs, and a RING domain, suggests that Np95 might control several protein--protein interactions and enzymatic activities required for S phase entry. The absolute requirement for Np95 in this critical phase of the cell cycle warrants further investigations on its possible role in malignant transformation.

Materials and methods
=====================

Cells and microinjection procedures
-----------------------------------

C2C12 myoblasts ([@bib35]) were cultured in collagen-coated dishes in DME supplemented with 10% FBS. Differentiation was induced by serum deprivation for 72 h ([@bib32]). Unless otherwise stated, 50 mM 1-β-[d]{.smallcaps}-arabinofuranosylcytosine (Ara-C) was added during the first 48 h to eliminate undifferentiated cells. Ara-C--purified myotubes contained \>90% of the nuclei in the culture.

For microinjections, morpholino-modified oligonucleotides (Gene-Tools Inc.) were prepared at a concentration of 0.5 μM. The following oligos were used in [Fig. 4](#fig4){ref-type="fig"}: antisense, 5′[CAT]{.ul}GATGCCGATGTACTCTCTCACG3′ (the antisense codon corresponding to ATG is underlined); and control (bearing four mismatches), 5′CAAGATCCCGATGTACTGTCTGACGCAAGATGCCGATGTACTGTCTGACG3′. Microinjection was performed with a microinjector (model Axiovert 100; ZEISS).

Adenoviruses
------------

The *dl520* and *dl312* adenoviruses have been described previously ([@bib12]; [@bib36]; [@bib34]). The Ad-cdk2 and Ad-cycE recombinant adenoviruses have also been described previously ([@bib18]). Ad-E2F-1 was a gift of J. Nevins (Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC; [@bib7]). The Ad-Np95 adenovirus was generated according to [@bib14] by placing the cDNA for Np95 ([@bib11]) under the control of the cytomegalovirus immediate-early promoter enhancer. This virus also expressed the green fluorescent protein under the control of a second copy of the cytomegalovirus promoter. All adenoviruses were grown and titrated in the permissive 293 cell line ([@bib13]). The multiplicity of infection (MOI) for all biological experiments is expressed as plaque-forming unit (pfu), as established by titration on 293 cells per infected cells.

RNA extraction, Northern blotting, and cDNA subtraction
-------------------------------------------------------

Total RNAs were prepared by guanidine-cesium chloride gradient according to published methods ([@bib29]). Poly(A)^+^ RNA was prepared with a commercial kit (Amersham Pharmacia Biotech), based on the oligo-dT method, according to the manufacturer\'s instructions. The cDNA subtraction was performed with the PCR select cDNA subtraction kit (CLONTECH Laboratories, Inc.) according to the manufacturer\'s instructions ([@bib8]).

Protein studies
---------------

Preparation of cellular lysates, immunoprecipitation, and immunoblotting were performed as described previously ([@bib10]). Immunofluorescence procedures were also as described previously ([@bib32]; [@bib18]). Antibodies used were as follows: rabbit antiserum to cycE (Santa Cruz Biotechnology, Inc.), mAb clone G3--245 to pRb (BD PharMingen; pRb in all figures), rabbit antiserum to pRb phosphorylated on serine 807/811 (Cell Signaling; ph-pRb in all figures), mAb against E2F-1 (a gift of K. Helin, European Institute of Oncology, Milan Italy), goat antiserum against lamin B (Santa Cruz Biotechnology, Inc.), rat Th-10a mAb to Np95 ([@bib23]), mouse mAb to BrdU (Becton Dickinson), and rabbit antiserum to muscle-specific myosin heavy chain (a gift of G. Cossu, Stem Cell Research Institute, Rome, Italy). In immunofluorescence experiments, mAbs were detected either with donkey anti--mouse Cy3 (red) or donkey anti--mouse FITC (green) secondary antibodies. The Np95 mAb was detected with a goat anti--rat Cy3 (red). pAbs were detected with donkey anti--rabbit FITC (green). Pictures were acquired with a color-chilled camera (model 3CCD-C5810; Hamamatsu Corporation). Blots were digitalized with an AGFA scan system. All images were managed with Adobe Photoshop^®^.
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